ATE377754T1 - Onkolytische viren zur bestimmung des phänotypus von neoplasmen - Google Patents
Onkolytische viren zur bestimmung des phänotypus von neoplasmenInfo
- Publication number
- ATE377754T1 ATE377754T1 AT03737795T AT03737795T ATE377754T1 AT E377754 T1 ATE377754 T1 AT E377754T1 AT 03737795 T AT03737795 T AT 03737795T AT 03737795 T AT03737795 T AT 03737795T AT E377754 T1 ATE377754 T1 AT E377754T1
- Authority
- AT
- Austria
- Prior art keywords
- neoplasms
- phenotype
- determining
- oncolytic viruses
- oncolytic
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/14—Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39203102P | 2002-06-28 | 2002-06-28 | |
| US44318803P | 2003-01-29 | 2003-01-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE377754T1 true ATE377754T1 (de) | 2007-11-15 |
Family
ID=30003222
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03737795T ATE377754T1 (de) | 2002-06-28 | 2003-06-25 | Onkolytische viren zur bestimmung des phänotypus von neoplasmen |
| AT07021569T ATE555388T1 (de) | 2002-06-28 | 2003-06-25 | Onkolytische viren zur bestimmung des phänotypus von neoplasmen |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07021569T ATE555388T1 (de) | 2002-06-28 | 2003-06-25 | Onkolytische viren zur bestimmung des phänotypus von neoplasmen |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US7306902B2 (de) |
| EP (2) | EP1520175B1 (de) |
| JP (1) | JP2005531306A (de) |
| CN (1) | CN1666105B (de) |
| AR (1) | AR039768A1 (de) |
| AT (2) | ATE377754T1 (de) |
| AU (2) | AU2003245760B2 (de) |
| BR (1) | BR0311983A (de) |
| CA (1) | CA2487824C (de) |
| DE (1) | DE60317331T2 (de) |
| DK (2) | DK1520175T3 (de) |
| ES (2) | ES2385845T3 (de) |
| IL (2) | IL165498A0 (de) |
| MX (1) | MXPA04012414A (de) |
| NZ (1) | NZ537116A (de) |
| PT (1) | PT1890151E (de) |
| SI (1) | SI1890151T1 (de) |
| TW (3) | TWI402345B (de) |
| WO (1) | WO2004003562A2 (de) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ425699A0 (en) | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
| US8491884B2 (en) * | 2000-05-03 | 2013-07-23 | Oncolytics Biotech Inc. | Virus clearance of neoplastic cells from mixed cellular compositions |
| US7306902B2 (en) * | 2002-06-28 | 2007-12-11 | Oncolyties Biotech Inc. | Oncolytic viruses as phenotyping agents for neoplasms |
| US20040115170A1 (en) * | 2001-11-30 | 2004-06-17 | Brown Earl Garnet | Oncolytic virus |
| WO2004009763A2 (en) | 2002-07-24 | 2004-01-29 | Arizona Board Of Regents | Use of vaccinia virus deleted for the e3l gene as a vaccine vector |
| AU2002953436A0 (en) | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
| US20070036758A1 (en) * | 2003-07-08 | 2007-02-15 | Bertram Jacobs | Mutants of vaccinia virus as oncolytic agents |
| WO2005111200A1 (en) * | 2004-05-17 | 2005-11-24 | Universite De Montreal | Novel strains of reoviruses and methods of uses thereof |
| US10668119B2 (en) | 2005-08-01 | 2020-06-02 | Virocure, Inc. | Attenuated reovirus |
| WO2007099401A2 (en) | 2005-08-01 | 2007-09-07 | University Technologies International, Inc. | Oncolytic attenuated reoviruses for treatment of proliferative disorders |
| CA2634591A1 (en) * | 2005-12-22 | 2007-07-05 | Memorial Sloan-Kettering Cancer Center | Method for detection of cancer cells using virus |
| US20070190032A1 (en) * | 2006-02-13 | 2007-08-16 | Oncolytics Biotech Inc. | Use of Local Immune Suppression to Enhance Oncolytic Viral Therapy |
| US10369171B2 (en) | 2007-03-13 | 2019-08-06 | Virocure, Inc. | Attenuated reoviruses for selection of cell populations |
| US9241998B2 (en) * | 2007-05-21 | 2016-01-26 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oncolytic RSV activity |
| CN102124335B (zh) * | 2008-05-22 | 2014-07-30 | 第一药品株式会社 | 基于肿瘤抑制因子的过度增生细胞对溶瘤病毒疗法的敏感性 |
| MX339014B (es) * | 2008-05-27 | 2016-05-09 | Oncolytics Biotech Inc | Modulacion de presion intersticial y suministro y distribucion viral oncolitica. |
| TW200950777A (en) * | 2008-05-27 | 2009-12-16 | Oncolytics Biotech Inc | Abrogating proinflammatory cytokine production during oncolytic reovirus therapy |
| US8481297B2 (en) * | 2009-01-08 | 2013-07-09 | Yale University | Compositions and methods of use of an oncolytic vesicular stomatitis virus |
| ES2385251B1 (es) | 2009-05-06 | 2013-05-06 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge | Adenovirus oncolíticos para el tratamiento del cáncer. |
| EP2670426B1 (de) | 2011-01-31 | 2017-05-10 | The General Hospital Corporation | Multimodale trail-moleküle und ihre verwendungen in zelltherapien |
| US8859256B2 (en) | 2011-10-05 | 2014-10-14 | Genelux Corporation | Method for detecting replication or colonization of a biological therapeutic |
| WO2013138522A2 (en) | 2012-03-16 | 2013-09-19 | Genelux Corporation | Methods for assessing effectiveness and monitoring oncolytic virus treatment |
| WO2013158265A1 (en) | 2012-04-20 | 2013-10-24 | Genelux Corporation | Imaging methods for oncolytic virus therapy |
| EP2877572B1 (de) | 2012-07-24 | 2018-11-28 | The General Hospital Corporation | Onkolytische virustherapie für resistente tumoren |
| WO2014035474A1 (en) | 2012-08-30 | 2014-03-06 | The General Hospital Corporation | Compositions and methods for treating cancer |
| US20140140959A1 (en) | 2012-10-05 | 2014-05-22 | Aladar A. Szalay | Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes |
| EP3082834B1 (de) * | 2013-12-11 | 2020-03-11 | The General Hospital Corporation DBA Massachusetts | Von stammzellen abgegebener onkolytischer herpes-simplex-virus und verfahren zur behandlung von hirntumoren |
| WO2015103438A2 (en) | 2014-01-02 | 2015-07-09 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
| ES2753391T3 (es) | 2014-10-14 | 2020-04-08 | Halozyme Inc | Composiciones de adenosina desaminasa 2 (ADA2), variantes de la misma y métodos de uso de las mismas |
| EP4122492A1 (de) | 2015-02-25 | 2023-01-25 | Memorial Sloan Kettering Cancer Center | Verwendung von inaktiviertem nichtreplizierendem modified-vaccinia-ankara-virus (mva) als monoimmuntherapie oder in kombination mit immun-checkpoint-blockierungsmitteln für solide tumoren |
| KR20180006916A (ko) | 2015-04-17 | 2018-01-19 | 메모리얼 슬로안-케터링 캔서 센터 | 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도 |
| JP7025339B2 (ja) | 2016-02-25 | 2022-02-24 | メモリアル スローン ケタリング キャンサー センター | 癌免疫療法のための、チミジンキナーゼの欠失を伴い、ヒトｆｌｔ３ｌまたはｇｍ－ｃｓｆの発現を伴うかまたは伴わない、複製可能な弱毒化ワクシニアウイルス |
| CN109152827B (zh) | 2016-02-25 | 2023-07-21 | 纪念斯隆凯特琳癌症中心 | 重组mva或表达人flt3l的mvaδe3l及其作为抗固体肿瘤的免疫治疗剂的用途 |
| EP4706777A2 (de) | 2016-04-15 | 2026-03-11 | Alpine Immune Sciences, Inc. | Immunmodulatorische proteine mit cd80-variante und verwendungen davon |
| IL262365B2 (en) | 2016-04-15 | 2024-11-01 | Alpine Immune Sciences Inc | Immunomodulatory proteins ICOS ligand variants and uses thereof |
| US10842835B2 (en) | 2016-05-25 | 2020-11-24 | Arizona Board Of Regents On Behalf Of Arizona State University | Oncolytic vaccinia virus mutants and using same for cancer treatment |
| US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| CN110088127A (zh) | 2016-07-28 | 2019-08-02 | 高山免疫科学股份有限公司 | Cd155变体免疫调节蛋白及其用途 |
| EP4023233B1 (de) * | 2016-09-27 | 2026-01-07 | Sator Therapeutics LLC | Rekombinante onkolytische viren und verwendungen davon |
| CA3040296A1 (en) | 2016-10-20 | 2018-04-26 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
| CN110546265A (zh) | 2017-02-09 | 2019-12-06 | 因达普塔治疗公司 | 工程化自然杀伤(nk)细胞及其组合物和方法 |
| EP3596114A2 (de) | 2017-03-16 | 2020-01-22 | Alpine Immune Sciences, Inc. | Cd80-variante immunmodulatorische proteine und verwendungen davon |
| PT3596116T (pt) | 2017-03-16 | 2023-12-04 | Alpine Immune Sciences Inc | Proteínas imunomoduladoras de pd-l1 variante e suas utilizações |
| JP2020511144A (ja) | 2017-03-16 | 2020-04-16 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｐｄ−ｌ２バリアント免疫調節タンパク質及びその使用 |
| EP3621646A4 (de) | 2017-05-12 | 2021-06-02 | Memorial Sloan Kettering Cancer Center | Mutanten des vaccinia-virus für die krebsimmuntherapie |
| SMT202600062T1 (it) | 2017-10-18 | 2026-03-09 | Alpine Immune Sciences Inc | Proteine immunomodulatrici del ligando di icos variante e composizioni e metodi correlati |
| SG11202006148UA (en) | 2018-01-03 | 2020-07-29 | Alpine Immune Sciences Inc | Multi-domain immunomodulatory proteins and methods of use thereof |
| US11505782B2 (en) | 2018-06-04 | 2022-11-22 | Calidi Biotherapeutics, Inc. | Cell-based vehicles for potentiation of viral therapy |
| KR102662837B1 (ko) | 2018-06-04 | 2024-05-03 | 카리디 바이오테라퓨틱스, 인크. | 바이러스 치료법의 강화를 위한 세포-기반 비히클 |
| US12065476B2 (en) | 2018-06-15 | 2024-08-20 | Alpine Immune Sciences, Inc. | PD-1 variant immunomodulatory proteins and uses thereof |
| EP3844276A2 (de) | 2018-08-28 | 2021-07-07 | Actym Therapeutics, Inc. | Manipulierte immunstimulierende bakterienstämme und verwendungen davon |
| BR112021004692A2 (pt) | 2018-09-15 | 2021-06-08 | Memorial Sloan Kettering Cancer Center | poxvírus recombinantes para imunoterapia de câncer |
| EP3876951A1 (de) | 2018-11-06 | 2021-09-15 | Calidi Biotherapeutics, Inc. | Verbesserte systeme für zellvermittelte onkolytische virustherapie |
| US12410402B2 (en) | 2018-11-21 | 2025-09-09 | Indapta Therapeutics, Inc. | Methods for expansion of natural killer (NK) cell subset and related compositions and methods |
| WO2020113141A2 (en) | 2018-11-30 | 2020-06-04 | Alpine Immune Sciences, Inc. | Cd86 variant immunomodulatory proteins and uses thereof |
| US12024709B2 (en) | 2019-02-27 | 2024-07-02 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| CN113748124A (zh) | 2019-02-27 | 2021-12-03 | 阿克蒂姆治疗有限公司 | 工程化以定植肿瘤、肿瘤驻留免疫细胞和肿瘤微环境的免疫刺激性细菌 |
| KR20230088306A (ko) | 2020-04-22 | 2023-06-19 | 인답타 세라뷰틱스 인코포레이티드 | 자연 살해(ｎｋ) 세포 조성물 및 이를 생성하는 방법 |
| WO2022147481A1 (en) | 2020-12-30 | 2022-07-07 | Ansun Biopharma Inc. | Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747469A (en) * | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
| US5670330A (en) * | 1992-09-29 | 1997-09-23 | Mcgill University | Anti-tumor agent assay using PKR |
| US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| ATE199568T1 (de) | 1993-02-16 | 2001-03-15 | Onyx Pharma Inc | Cytopatische viren zur therapie und prophylaxe der neoplasie |
| EP2009119A1 (de) | 1993-04-30 | 2008-12-31 | Wellstat Biologics Corporation | Zusammensetzungen zur Behandlung von Krebs mittels Viren |
| CA2178902A1 (en) | 1993-12-14 | 1995-06-22 | The Johns Hopkins University School Of Medicine | Controlled release of pharmaceutically active substances for immunotherapy |
| WO1995032300A1 (en) | 1994-05-23 | 1995-11-30 | University Of Medicine & Dentistry Of New Jersey | Selective biological destruction of tumor cells |
| US5585096A (en) | 1994-06-23 | 1996-12-17 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
| US5840502A (en) | 1994-08-31 | 1998-11-24 | Activated Cell Therapy, Inc. | Methods for enriching specific cell-types by density gradient centrifugation |
| US6777177B1 (en) * | 1997-10-10 | 2004-08-17 | Vanderbilt University | Mammalian genes involved in viral infection and tumor suppression |
| US6110461A (en) | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
| US6136307A (en) * | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
| CA2508238C (en) | 1997-08-13 | 2008-01-15 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
| US7780962B2 (en) * | 1997-10-09 | 2010-08-24 | Wellstat Biologics Corporation | Treatment of neoplasms with RNA viruses |
| IL135507A0 (en) | 1997-10-09 | 2001-05-20 | Pro Virus Inc | Treatment of neoplasms with viruses |
| US6475481B2 (en) | 1997-11-18 | 2002-11-05 | Canji Inc | Purging of stem cell products |
| CA2323067A1 (en) | 1998-03-12 | 1999-09-16 | The Trustees Of The University Of Pennsylvania | Producer cells for replication selective viruses in the treatment of malignancy |
| ATE318176T1 (de) | 1998-08-31 | 2006-03-15 | Julian L Ambrus | Verfahren zur entfernung von hiv und anderen viren aus blut |
| JP2003530301A (ja) | 1999-04-15 | 2003-10-14 | ウェルスタット バイオロジクス コーポレイション | ウイルスを用いた新生物の処置 |
| DE19934788B4 (de) * | 1999-07-27 | 2004-05-27 | T-Mobile Deutschland Gmbh | Verfahren zur automatischen Anpassung von Daten an die Fähigkeiten einer Nutzer-Software |
| NZ517573A (en) | 1999-09-17 | 2004-02-27 | Pro Virus Inc | Sequences of the oncolytic virus strain vesicular stromatitis virus (VSV) |
| EP1955703A1 (de) | 1999-11-12 | 2008-08-13 | Oncolytics Biotech Inc. | Viren für die Behandlung von zellulären, proliferativen Erkrankungen |
| AUPQ425699A0 (en) | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
| AR028040A1 (es) | 2000-05-03 | 2003-04-23 | Oncolytics Biotech Inc | Remocion de virus de celulas neoplasticas a partir de composiciones celulares mixtas |
| US7306902B2 (en) * | 2002-06-28 | 2007-12-11 | Oncolyties Biotech Inc. | Oncolytic viruses as phenotyping agents for neoplasms |
| AR028039A1 (es) | 2000-05-03 | 2003-04-23 | Oncolytics Biotech Inc | Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas |
| HK1052950B (en) * | 2000-06-26 | 2005-06-24 | Wellstat Biologics Corporation | Purging of cells using viruses |
| WO2002004596A2 (en) | 2000-07-07 | 2002-01-17 | President And Fellows Of Harvard College | Diagnosing and treating cancer cells using mutant viruses |
| BR0115235A (pt) | 2000-11-09 | 2003-10-14 | Oncolytics Biotech Inc | Métodos de determinar a suscetibilidade de uma célula à infecção por reovìrus, e, uso de uma composição compreendendo um ou mais reovìrus |
| US20030138405A1 (en) * | 2001-04-17 | 2003-07-24 | Juan Fueyo | Conditionally replicative adenovirus to target the Rb and Rb-related pathways |
-
2003
- 2003-06-24 US US10/602,024 patent/US7306902B2/en not_active Expired - Lifetime
- 2003-06-25 NZ NZ537116A patent/NZ537116A/en unknown
- 2003-06-25 AU AU2003245760A patent/AU2003245760B2/en not_active Expired
- 2003-06-25 CA CA2487824A patent/CA2487824C/en not_active Expired - Lifetime
- 2003-06-25 DE DE60317331T patent/DE60317331T2/de not_active Expired - Lifetime
- 2003-06-25 AT AT03737795T patent/ATE377754T1/de not_active IP Right Cessation
- 2003-06-25 ES ES07021569T patent/ES2385845T3/es not_active Expired - Lifetime
- 2003-06-25 WO PCT/CA2003/000951 patent/WO2004003562A2/en not_active Ceased
- 2003-06-25 EP EP03737795A patent/EP1520175B1/de not_active Expired - Lifetime
- 2003-06-25 PT PT07021569T patent/PT1890151E/pt unknown
- 2003-06-25 EP EP07021569A patent/EP1890151B1/de not_active Expired - Lifetime
- 2003-06-25 MX MXPA04012414A patent/MXPA04012414A/es active IP Right Grant
- 2003-06-25 SI SI200332164T patent/SI1890151T1/sl unknown
- 2003-06-25 AT AT07021569T patent/ATE555388T1/de active
- 2003-06-25 DK DK03737795T patent/DK1520175T3/da active
- 2003-06-25 DK DK07021569.4T patent/DK1890151T3/da active
- 2003-06-25 ES ES03737795T patent/ES2292981T3/es not_active Expired - Lifetime
- 2003-06-25 JP JP2004516379A patent/JP2005531306A/ja active Pending
- 2003-06-25 CN CN03815353.XA patent/CN1666105B/zh not_active Expired - Lifetime
- 2003-06-25 BR BR0311983-1A patent/BR0311983A/pt not_active IP Right Cessation
- 2003-06-26 TW TW098118162A patent/TWI402345B/zh not_active IP Right Cessation
- 2003-06-26 TW TW092117377A patent/TWI327167B/zh not_active IP Right Cessation
- 2003-06-26 TW TW098135545A patent/TWI334444B/zh not_active IP Right Cessation
- 2003-06-26 AR ARP030102317A patent/AR039768A1/es unknown
-
2004
- 2004-12-01 IL IL16549804A patent/IL165498A0/xx active IP Right Grant
-
2007
- 2007-05-30 US US11/807,771 patent/US20080014577A1/en not_active Abandoned
-
2008
- 2008-08-28 AU AU2008207579A patent/AU2008207579B2/en not_active Expired
-
2010
- 2010-01-05 US US12/652,289 patent/US8222036B2/en not_active Expired - Fee Related
-
2012
- 2012-06-04 IL IL220139A patent/IL220139A/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE377754T1 (de) | Onkolytische viren zur bestimmung des phänotypus von neoplasmen | |
| NO2017058I1 (no) | HPV 58 L1 protein | |
| EP1636250A4 (de) | Selbstorganisierendes, modifikationen enthaltende peptide und verfahren zu deren anwendung | |
| NO2017012I1 (no) | HPV 45 L1 protein | |
| DK1501921T3 (da) | Forbedrede virusrensningsmetoder | |
| NO2012018I1 (no) | Canakinumab eller direkte ekvivalenter derav | |
| EP1357809A4 (de) | Hygienisierung von nahrungsmitteln | |
| ATE506104T1 (de) | Hepatitis-c-virus-hemmer | |
| DE50306850D1 (de) | Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen | |
| DE602004028763D1 (de) | Te zur behandlung von virenerkrankungen | |
| DE50204802D1 (de) | Sensor zur sitzbelegungserkennung | |
| DE60136477D1 (de) | Retinoide zur behandlung von emphysem | |
| DE60308203D1 (de) | Gerät zur bestimmung des stimulationschwellwertes | |
| DE60319456D1 (de) | Gerät zur Bestimmung von Papierqualität | |
| DE60237639D1 (de) | Methode zur bestimmung der biologischen aktivität von difibrotid | |
| DE60142754D1 (de) | Electrophoretische Kasette zur Detektion von Biopolymeren | |
| DE60304884D1 (de) | Segmentierte reifenform zur verringerung von grat | |
| DE602004002601D1 (de) | Erkennung von Multiplexern und Austausch von Parametern | |
| DE602004022046D1 (de) | Herstellung von kleinen teilchen | |
| NO20015325D0 (no) | Defekt-deteksjon | |
| DE10290563D2 (de) | Mittel zur Hemmung von Tumorzellen | |
| DE60200713D1 (de) | Zusammensetzung enthaltend getrocknetes Vollei zur Behandlung von Hepatitis | |
| DE50302846D1 (de) | Gelenkige aufhängung | |
| EP1511864A4 (de) | Virale capsidaggregat-zwischenstoffe | |
| DE60200296D1 (de) | Gerät zur Detektion von Vorsatzlöchern |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1520175 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |